Search

The biological roles of the newly identified long non-coding RNA family with sequence similarity 83 member H antisense 1 (FAM83H-AS1) in esophageal squamous cell carcinoma (ESCC) have remained largely elusive. In the present study, it was determined that, in comparison with paired para-tumorous tissues or normal esophageal epithelial cells, FAM83H-AS1 expression in cancer tissues and cell lines was markedly upregulated. Furthermore, FAM83H-AS1 expression was significantly elevated in patients with ESCC and lymph node metastasis or a late TNM stage, while no association with any other clinicopathological characteristics was detected. Furthermore, the overall and disease-free survival, as assessed by the Kaplan-Meier method, were significantly shortened in patients with high FAM83H-AS1 expression. A functional study then uncovered that knockdown of FAM83H-AS1 significantly suppressed the proliferation and migration of ESCC cells. The present results suggested that FAM83H-AS1 may facilitate the malignant progression of ESCC and may be utilized as a prognostic predictor and possibly a novel therapeutic target in ESCC that warrants further exploration. [ABSTRACT FROM AUTHOR]

To explore the expression level and to investigate the clinical associations of the long non-coding RNA (lncRNA) FAM83H-AS1 in gastric cancer. The expression level of FAM83H-AS1 were explored by quantitative reverse transcription PCR (qRT-PCR). The Cox regression models as well as log-rank test were utilized to investigate whether FAM83H-AS1 expression could be used as a prognosis predictor. The value of FAM83H-AS1 as a diagnostic biomarker was evaluated by receiver operating curves (ROC). Aberrantly upregulation of FAM83H-AS1 was identified in gastric cancer in comparison with that in normal tissues. We also found that upregulated FAM83H-AS1 was a risk factor relating to OS and DFS. The area under curve (AUC) was 0.8603 and 0.6778 for gastric cancer and lymph node metastasis, respectively. Our results indicated that FAM83H-AS1 may function as an oncogene in gastric cancer and could be used as a prognosis predictor or diagnostic biomarker in gastric cancer. [ABSTRACT FROM AUTHOR]